Timothy J Ziemlewicz1, J Louis Hinshaw2, Meghan G Lubner2, Christopher L Brace3, Marci L Alexander2, Parul Agarwal4, Fred T Lee2. 1. Department of Radiology, University of Wisconsin-Madison, 600 Highland Ave., E3/366 CSC, Madison, WI 53792.. Electronic address: tziemlewicz@uwhealth.org. 2. Department of Radiology, University of Wisconsin-Madison, 600 Highland Ave., E3/366 CSC, Madison, WI 53792. 3. Department of Radiology, University of Wisconsin-Madison, 600 Highland Ave., E3/366 CSC, Madison, WI 53792.; Department of Biomedical Engineering, University of Wisconsin-Madison, 600 Highland Ave., E3/366 CSC, Madison, WI 53792.; Department of Medical Physics, University of Wisconsin-Madison, 600 Highland Ave., E3/366 CSC, Madison, WI 53792. 4. Section of Hepatology, Department of Medicine, University of Wisconsin-Madison, 600 Highland Ave., E3/366 CSC, Madison, WI 53792.
Abstract
PURPOSE: To retrospectively review the results of hepatocellular carcinoma (HCC) treatment with a high-power, gas-cooled, multiantenna-capable microwave device. MATERIALS AND METHODS: A total of 107 HCCs in 75 patients (65 men) with a mean age of 61 years (range, 44-82 y) were treated via percutaneous approach. Combination microwave ablation and transarterial chemoembolization was performed for 22 tumors in 19 patients with tumors larger than 4 cm (n = 10), tumors larger than 3 cm with ill-defined margins (n = 7), or lesions not identified with ultrasonography (n = 5). Mean tumor size was 2.1 cm (range, 0.5-4.2 cm), with median follow-up of 14 months, for ablation alone; compared with 3.7 cm (range, 1.0-7.0 cm) and 12 months, respectively, for combination therapy. All procedures were performed with a single microwave system (Certus 140) with one to three 17-gauge antennas. RESULTS: Mean ablation time was 5.3 minutes (range, 1-11.5 min). All treatments were considered technically successful in a single session. Primary technique effectiveness rates were 91.6% (98 of 107) overall, 93.7% (89 of 95) for tumors 4 cm or smaller, and 75.0% (nine of 12) for tumors larger than 4 cm; and 91.8% (78 of 85) for ablation alone and 90.9% (20 of 22) for combination therapy. There was no major complication or procedure-related mortality. The overall survival rate was 76.0% at a median 14-month clinical follow-up, with most deaths related to end-stage liver disease (n = 11) or multifocal HCC (n = 5). CONCLUSIONS: Treating HCC with a gas-cooled, multiantenna-capable microwave ablation device is safe, with promising treatment effectiveness.
PURPOSE: To retrospectively review the results of hepatocellular carcinoma (HCC) treatment with a high-power, gas-cooled, multiantenna-capable microwave device. MATERIALS AND METHODS: A total of 107 HCCs in 75 patients (65 men) with a mean age of 61 years (range, 44-82 y) were treated via percutaneous approach. Combination microwave ablation and transarterial chemoembolization was performed for 22 tumors in 19 patients with tumors larger than 4 cm (n = 10), tumors larger than 3 cm with ill-defined margins (n = 7), or lesions not identified with ultrasonography (n = 5). Mean tumor size was 2.1 cm (range, 0.5-4.2 cm), with median follow-up of 14 months, for ablation alone; compared with 3.7 cm (range, 1.0-7.0 cm) and 12 months, respectively, for combination therapy. All procedures were performed with a single microwave system (Certus 140) with one to three 17-gauge antennas. RESULTS: Mean ablation time was 5.3 minutes (range, 1-11.5 min). All treatments were considered technically successful in a single session. Primary technique effectiveness rates were 91.6% (98 of 107) overall, 93.7% (89 of 95) for tumors 4 cm or smaller, and 75.0% (nine of 12) for tumors larger than 4 cm; and 91.8% (78 of 85) for ablation alone and 90.9% (20 of 22) for combination therapy. There was no major complication or procedure-related mortality. The overall survival rate was 76.0% at a median 14-month clinical follow-up, with most deaths related to end-stage liver disease (n = 11) or multifocal HCC (n = 5). CONCLUSIONS: Treating HCC with a gas-cooled, multiantenna-capable microwave ablation device is safe, with promising treatment effectiveness.
Authors: Christopher L Brace; Paul F Laeseke; Lisa A Sampson; Tina M Frey; Daniel W van der Weide; Fred T Lee Journal: Radiology Date: 2007-02 Impact factor: 11.105
Authors: Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg Journal: Radiology Date: 2003-02 Impact factor: 11.105
Authors: Michael J Ryan; Jonathon Willatt; Bill S Majdalany; Ania Z Kielar; Suzanne Chong; Julie A Ruma; Amit Pandya Journal: World J Hepatol Date: 2016-01-28
Authors: Maria Franca Meloni; Jason Chiang; Paul F Laeseke; Christoph F Dietrich; Angela Sannino; Marco Solbiati; Elisabetta Nocerino; Christopher L Brace; Fred T Lee Journal: Int J Hyperthermia Date: 2016-08-02 Impact factor: 3.914
Authors: Wenjun Yang; Tomy Varghese; Timothy Ziemlewicz; Marci Alexander; Meghan Lubner; James Louis Hinshaw; Shane Wells; Fred T Lee Journal: Ultrasound Med Biol Date: 2017-06-05 Impact factor: 2.998
Authors: Wenjun Yang; Timothy J Ziemlewicz; Tomy Varghese; Marci L Alexander; Nicholas Rubert; Atul N Ingle; Meghan G Lubner; James L Hinshaw; Shane A Wells; Fred T Lee; James A Zagzebski Journal: Ultrasound Med Biol Date: 2016-09-02 Impact factor: 2.998
Authors: Jason Chiang; Mircea Cristescu; Matthew H Lee; Anna Moreland; J Louis Hinshaw; Fred T Lee; Christopher L Brace Journal: Radiology Date: 2016-06-03 Impact factor: 11.105